Lockheed Martin: Q2 Beat Raises Guidance, but Missile Concentration and Execution Risks Persist

What happened

Lockheed Martin reported strong Q2 2026 results, beating estimates and raising full-year guidance on record backlog of $230.4 billion, driven by a $35 billion THAAD contract and surging missile demand. However, the backlog increase is heavily concentrated in the Missiles and Fire Control segment, while Aeronautics still recorded $315 million in charges on F-16, C-130, and other programs. The stock has rallied to $582.6, leaving it at 21.4x earnings, which already prices in much of the replenishment story. Our WAIT rating reflects that near-term returns depend on funded PAC-3 awards and sustained MFC margins above 14%, outcomes that are not yet assured. Until those catalysts materialize, the risk/reward at current levels is balanced rather than compelling.

Implication

The guidance raise and record backlog confirm Lockheed Martin's central role in the global defense spending cycle, but the stock already trades near our base-case implied value of $605. The thesis hinges on whether missile orders broaden into funded PAC-3 awards and whether MFC margins can sustain above 14%, while Aeronautics stops taking charges. We see asymmetric risk if these milestones are missed, as the market may reprice the stock to our bear case of $515. Investors should monitor the upcoming fiscal year 2026 appropriations for concrete PAC-3 awards and the next two quarterly filings for any new profit adjustments on legacy aircraft programs.

Thesis delta

The Q2 beat and guidance raise reinforce Lockheed's missile demand narrative but do not alter our cautious stance. The risks of concentrated backlog, fixed-price execution, and stretched valuation remain unchanged, keeping our WAIT rating and $650 trim target intact.